Breakdown | TTM | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 14.32B | 14.95B | 14.54B | 8.45B | 7.44B | 5.31B |
Gross Profit | 6.48B | 6.87B | 6.87B | 5.03B | 4.85B | 3.51B |
EBITDA | 1.72B | 3.01B | 1.87B | 1.30B | 1.98B | 1.27B |
Net Income | 1.52B | 1.48B | 617.68M | 812.39M | 1.29B | 725.97M |
Balance Sheet | ||||||
Total Assets | 15.36B | 15.55B | 15.16B | 9.35B | 8.54B | 7.13B |
Cash, Cash Equivalents and Short-Term Investments | 7.13B | 7.28B | 5.39B | 6.14B | 5.70B | 4.70B |
Total Debt | 3.04B | 3.16B | 3.81B | 179.12M | 136.32M | 202.90M |
Total Liabilities | 5.67B | 6.10B | 6.57B | 1.49B | 1.56B | 1.55B |
Stockholders Equity | 9.69B | 9.45B | 8.30B | 7.59B | 6.71B | 5.35B |
Cash Flow | ||||||
Free Cash Flow | 0.00 | 1.63B | 494.10M | 691.01M | 1.11B | 758.87M |
Operating Cash Flow | 0.00 | 1.89B | 600.07M | 853.23M | 1.36B | 930.30M |
Investing Cash Flow | 0.00 | 1.27B | -5.01B | -422.88M | -345.39M | -469.23M |
Financing Cash Flow | 0.00 | -1.27B | 3.67B | 7.08M | -15.44M | 1.11B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
81 Outperform | ¥17.10B | 9.87 | 0.58% | -12.13% | 291.07% | ||
79 Outperform | ¥18.70B | 17.07 | 2.19% | 12.51% | 9.68% | ||
70 Outperform | ¥20.15B | 20.57 | 1.53% | 17.20% | 20.25% | ||
67 Neutral | ¥10.82B | 22.19 | 2.70% | 9.21% | -20.04% | ||
60 Neutral | HK$15.71B | 5.67 | -7.43% | 4.09% | 11.60% | -21.06% | |
45 Neutral | ¥10.18B | ― | ― | -79.38% | -1239.83% | ||
43 Neutral | ¥16.30B | 4,465.71 | 1.55% | -7.98% | -181.00% |
MedPeer, Inc. announced amendments to its previously declared management buyout (MBO) and tender offer process, initiated by NMT, Inc., aimed at delisting MedPeer’s shares. The tender offer period has been extended to provide shareholders more time to decide on tendering their shares, with the period now concluding on July 9, 2025. This strategic move is intended to increase the likelihood of a successful tender offer, although the tender price remains unchanged for now.
MedPeer, Inc. has announced an amendment to the ongoing tender offer by NMT, Inc. for its share certificates. The tender offer period has been extended by 10 business days, now concluding on July 9, 2025, to give shareholders more time to consider their participation. This extension aims to increase the likelihood of the tender offer’s completion, although the tender offer price remains unchanged for now.
MedPeer, Inc. announced amendments to its previously published notice regarding the implementation of a Management Buyout (MBO) and a recommendation to tender shares. The amendments clarify the intentions of Mr. Yo Iwami, a significant shareholder, to release collateralized shares and participate in the tender offer. The company plans to finance the tender offer through a bank loan from MUFG Bank and an equity investment, with the acquired shares and certain company assets pledged as collateral.
MedPeer, Inc. has announced a management buyout (MBO) involving a tender offer by NMT, Inc. to purchase its common shares, with the intention of taking the company private and delisting its shares. The board has expressed support for the tender offer, recommending shareholders to tender their shares, while leaving stock acquisition rights holders to decide independently. This move is expected to retract MedPeer’s plan for compliance with continued listing criteria, impacting its market presence and shareholder dynamics.
NMT, Inc. has announced a tender offer to acquire all shares of MedPeer, Inc., aiming to delist the company from the Tokyo Stock Exchange. This move, characterized as a management buyout, will see NMT’s founder, Yo Iwami, maintaining involvement in MedPeer’s operations, potentially impacting stakeholders by consolidating control and potentially reshaping the company’s strategic direction.
MedPeer, Inc. reported a decline in its consolidated financial results for the six months ended March 31, 2025, with net sales and operating profits experiencing significant decreases compared to the previous year. Despite the downturn in sales, the company saw a substantial increase in profit attributable to owners of the parent, indicating improved efficiency or cost management. The forecast for the fiscal year ending September 30, 2025, suggests further declines in sales and profits, posing challenges for the company’s future growth and market positioning.
MedPeer, Inc. has announced its support for a tender offer by NMT, Inc. to purchase its common stock and stock acquisition rights, with plans to delist the company shares following the offer. This decision leads to the retraction of MedPeer’s previously announced compliance plan for continued listing criteria, indicating a strategic shift in the company’s market approach and potential implications for its shareholders.
MedPeer, Inc. announced a revision to its dividend forecast for the fiscal year ending September 2025, deciding not to distribute year-end dividends. This decision aligns with the company’s support for a tender offer by NMT, Inc., which aims to take MedPeer private and delist its shares. The tender offer price assumes no year-end dividends, reflecting a strategic shift in the company’s financial planning and shareholder returns policy.